Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Clinical trials in non-small cell lung cancer (NSCLC) reveal that IL-6 targeted therapy relieves NSCLC-related anemia and cachexia, although other clinical effects require further study.
|
24260500 |
2013 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Systemic IL-6 overexpression in precachectic tumor-bearing Apc<sup>Min/+</sup> mice accelerated cachexia development, which coincided with suppressed basal and eccentric contraction-induced muscle protein synthesis.
|
29641213 |
2018 |
Cachexia
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
The association of SELP-rs6136, IL6-rs1800796 and AKT1-rs1130233 polymorphisms with cachexia as well as the correlation between cachexia and the candidate polymorphisms and overall survival were analyzed.
|
25238546 |
2014 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
The metabolic reduction in cachectic cancer patients was potentially related to the elevated serum level of interleukin-6.
|
30713247 |
2019 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
IL-6 triggers oncogenic/angiogenic signals and the cytokine-dependent pro-cachexia cascade.
|
24886605 |
2014 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
At the protein level, TNF-alpha was found expressed only in CIX, whereas IL-1 and IL-6 were not cachexia specific.
|
17878525 |
2007 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Advanced cancers are associated with a chronic inflammation, especially high interleukin-6 (IL-6) and with various levels of adipokines (leptin and adiponectin), while ghrelin counteracts the anorexigenic effect of leptin in cancer-induced anorexia-cachexia syndrome.
|
31794851 |
2020 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
A marked increase (5-fold) in IL-6 as a result of the interaction between the presence of cachexia and the presence of tumour was observed in the subcutaneous tissue of the patients, yet not in the visceral depot.
|
23200412 |
2013 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
A highly sensitive ELISA confirmed the multiplex result for increased IL-6 in cachectic patients (P = 0.02).
|
18006755 |
2007 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
We previously found that the human TOV21G cells secrete IL-6 that induces autophagy in reporter cells and cachexia in mice.
|
31436048 |
2020 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Based on these findings, we conclude that chronic inflammation (especially that mediated by IL-6) might promote cancer cachexia by regulating WAT lipolysis in early-stage cachexia and browning in late-stage cachexia.
|
29338749 |
2018 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
However, since release of IL-6 is frequent in HCC, especially in its more advanced stages, the use of agents like curcumin or DHMEQ might be beneficial to counteract its adverse systemic effects (e.g., cachexia).
|
17261774 |
2006 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these preclinical findings identify trans-signalling via STAT3 as the signalling modality by which IL-6 promotes muscle wasting in lung cancer cachexia, and therefore support the clinical evaluation of the IL-6 trans-signalling/STAT3 axis as a therapeutic target in advanced lung cancer patients presenting with cachexia.
|
27893707 |
2017 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
The serum level of the lipopolysaccharide-binding protein, often presented as a reflection of the bacterial antigen load, was not only increased in cachectic mice and cancer patients, but also strongly correlated with the serum IL-6 level and predictive of death and cachexia occurrence in these patients.
|
29719601 |
2018 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Others and we have shown that IL-6 alone is sufficient to induce cachexia both <i>in vitro</i> and <i>in vivo</i>.
|
28149280 |
2016 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
This relationship in the female warrants further investigation, as we have shown that the ability of IL-6 to induce cachexia differs between the sexes.
|
28292759 |
2017 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells.
|
21325484 |
2011 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
In lung cancer patients, were cachexia is prevalent, there was a significant correlation between elevated IL-6 expression in the tumor and poor prognosis of the patients.
|
28515477 |
2017 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Moreover, IL-6 is a pathophysiological factor in several hyperproliferative diseases and the paraneoplastic syndromes that often accompany cancer, such as cachexia and osteoporosis; thus, anti-IL-6 therapy would be useful in treating these entities as well.
|
16083340 |
2005 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
IL-6 overexpression in cachectic patients is related to the ability of certain tumors to sensitize PBMC and induce cytokine expression in cachectic PBMC.
|
16115919 |
2005 |
Cachexia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Overall, these results demonstrate short-term PDTC treatment to cachectic mice attenuated cancer-induced disruptions to muscle and liver signaling, and these changes were independent to altered tumor burden and circulating IL-6.
|
27449092 |
2016 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Lastly, the correlations between plasma interleukin-6 (IL-6) and lipid metabolism parameters in cachexia patients of different genders were analyzed.
|
31788012 |
2019 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
In cancer, the pro-inflammatory cytokine interleukin-6 (IL-6) is considered a mediator of cachexia and a potential biomarker, but the relationship between IL-6, weight loss, and cancer stage is unknown.
|
30497874 |
2019 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest that KPL-4 cells may be useful in the development of new strategies against breast cancer overexpressing the Erb B family receptors and against IL-6-induced cachexia.
|
10070858 |
1999 |
Cachexia
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention.
|
17878525 |
2007 |